Explore This Research Award in CaptureIQ
Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.
Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- BLOTTING INNOVATIONS, INC
- Proposal award date
- 2022-09-22
- Contract end date
- 2023-09-21
- UEI
- PXLEUBUM3JS7
- Solicitation number
- PA21-262
- Topic code
- 400
Research abstract
PROJECT SUMMARY
The goal of this Phase I STTR is for Blotting Innovations, LLC to establish feasibility of a commercializable
mesowestern—a high-throughput, affordable western blotting technique that we recently developed.
Western blotting is a technique for molecular-weight-resolved analysis of proteins and their post-translational
modifications that is practiced today almost identically to when it was first introduced in the late 1970s. It remains
one of the most widely-used protein assays across biomedical research, perhaps the most used in the past 10
years. Major reasons are that it is low-cost, often a gold standard, and well-established in most labs. Yet, western
blotting has been refractory to scale up, typically limited to ~10 samples per run. Capillary electrophoresis-based
separation in automated apparati has been developed that increase throughput with smaller samples, but are
expensive and can be sensitive to sample preparation. The microwestern uses piezoelectric pipetting for up to
96 blots at a time in a standard footprint; however, the piezoelectric apparatus imposes capital cost and technical
difficultly deterrents. We established the mesowestern that analyzes over 300 samples with a similar footprint,
affordability, and ease-of-use as traditional western blots, and with ~10-fold lower sample size requirements.
Our main products are a precast mesowestern gel that is loadable by a low-cost pipetting robot (opentrons) and
a novel yet affordable tank for immersed horizontal electrophoresis of the loaded precast gel. A main innovation
is a customizable gel casting device that produces polyacrylamide gels with hundreds of ~1 uL wells, and
associated protocols for robust gel casting and electrophoresis. Another main innovation is immersed horizontal
tank electrophoresis for polyacrylimide gels; only semi-dry horizontal (microwestern) or immersed vertical tank
(traditional) are currently available. Phase I Hypothesis. Can precast mesowestern gels be robustly-loaded
robotically, and then subjected to immersed horizontal tank electrophoresis? We hypothesize that this can be
accomplished by designing a rigid insert that holds the gel during casting and shipping but also fits into (i)
opentrons pipetting robots and (ii) a low-cost, horizontal immersed electrophoresis apparatus. We have two Aims
that will establish feasibility of the product by testing this hypothesis. In Aim 1, we will establish robust robotic
loading of shipped, precast mesowestern gels. We focus on Opentrons micropipetting robots that are easy to
use and very affordable. In Aim 2, we will establish robust electrophoresis of robotically-loaded mesowestern
gels. Success in each aim is defined by variability (CV%) across analytes and technicians to be andlt;10%. We
expect to have a beta-testable product at the end of Phase I. Phase II would focus on expanding to different
sample types (e.g. Immunoprecipitation-western) and across antibodies, as well as on robust transfer to
membrane (another main variability source). Our market is academic research labs and pre-clinical
pharmaceutical Randamp;D labs.PROJECT NARRATIVE
Proteins and their post-translational modifications functionally control most of biology. Western blotting is a
reliable method for analyzing them but has remained largely unchanged for over 40 years, and is low throughput.
This proposal develops a feasible product for the mesowestern technology, which enables high-throughput
western blotting with minimal deviation from the already trusted protocols.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
Research funding history
3 SBIR/STTR records share this UEI (2022–2025). Reported award amounts total $1,655,694. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services
Agency intelligence
Department of Health and Human Services
Back to SBIR/STTR Research Awards